BiotechTube

ONO-2952 + Placebo comparator

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome (IBS)

Conditions

Irritable Bowel Syndrome (IBS)

Trial Timeline

Jun 1, 2013 → —

NCT ID
NCT01887002

About ONO-2952 + Placebo comparator

ONO-2952 + Placebo comparator is a phase 2 stage product being developed by Ono Pharmaceutical for Irritable Bowel Syndrome (IBS). The current trial status is terminated. This product is registered under clinical trial identifier NCT01887002. Target conditions include Irritable Bowel Syndrome (IBS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01887002Phase 2Terminated

Competing Products

20 competing products in Irritable Bowel Syndrome (IBS)

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52
YM060 + PlaceboAstellas PharmaPhase 3
77
Ramosetron + PlaceboAstellas PharmaApproved
85
Ramosetron + PlaceboAstellas PharmaApproved
85
YM060Astellas PharmaPhase 3
77
YM060 + placeboAstellas PharmaPhase 2
52
YM060Astellas PharmaPhase 3
77
linaclotide + PlaceboAstellas PharmaPhase 3
77
RamosetronAstellas PharmaPre-clinical
23
YM060Astellas PharmaPhase 2
52
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
52
duloxetineEli LillyApproved
85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
77
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
77
Eluxadoline + PlaceboAbbViePhase 2
52
Placebo + LinaclotideAstraZenecaPhase 3
77
TegaserodNovartisPre-clinical
23
DNK333NovartisPhase 2
52
SMS995 + PlaceboNovartisPhase 1
33
DNK333 + PlaceboNovartisPhase 2
52

Other Products from Ono Pharmaceutical

Sivelestat sodium hydrate + Sivelestat sodium hydrateApproved
85
Abatacept + Placebo matching with Abatacept + MethotrexateApproved
85
Rivastigmine transdermal patchApproved
85
Sitagliptin phosphatePhase 3
77
ONO-4538 + Carboplatin + Paclitaxel + Bevacizumab + PlaceboPhase 3
77